08:50 AM EDT, 09/09/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) on Monday said new data from two of its preclinical programs were presented at the Promise of Interleukin-2 Conference held in Paris, France.

The first presentation outlined MDNA209's potential to treat autoimmune diseases, including high grade graft-versus-host-disease (GvHD) which has a 1-year survival rate of only 40%. The initial preclinical data, utilizing an animal model, sowed MDNA209 potential to "downregulate" the immune system, with therapeutic potential for GvHD and autoimmune diseases. MDNA209 was able to extend overall survival by 400% in the animal.

The second presentation was on MDNA113, which targets tumors. Its efficacy was significantly enhanced in mice harboring certain engineered tumors. According to the statement, this highlighted MDNA113's potential to treat immunologically "cold tumors" such as pancreatic, prostate, ovarian, and breast cancers.